Your session is about to expire
← Back to Search
Neoadjuvant and Adjuvant Abiraterone + Apalutamide for Prostate Cancer
Study Summary
This trial is testing whether androgen deprivation before surgery can improve pathologic response and biomarkers in localized prostate cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 26 Patients • NCT03043807Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had hormone therapy for prostate cancer, but not specific treatments.I have received treatments like chemotherapy, radiation, or immunotherapy for prostate cancer.I am eligible for prostate removal surgery as per my doctor's assessment.I haven't had serious heart problems in the last 6 months.I have a history of seizures or take medication that could cause them.I have severe liver problems.I do not have stomach or bowel problems that affect how I absorb medicine.I need to take more than 10 mg of prednisone daily for another health issue.I have not had major surgery or radiation therapy in the last 30 days.I do not have any infections or conditions that prevent me from using steroids.My prostate cancer is mainly adenocarcinoma, confirmed by a specialized review.My scans show no signs of cancer spread to other parts.I can carry out all my daily activities without help.My blood tests for organ and bone marrow function are normal.I stopped taking any seizure-risk increasing meds a week before the study.I have had at least 6 core biopsies, with 3 showing cancer.My prostate cancer has a Gleason score of 7 or higher, and my PSA is over 20 ng/dL or it's at stage T3.I haven't taken azole drugs in the last two weeks.I am taking medications that could affect how certain drugs work in my body.I am a man aged 18 or older.I have had issues with my pituitary or adrenal glands.
- Group 1: Arm 1A: AAPL Neoadjuvant Therapy [Part 1]
- Group 2: Arm 1B: APL Neoadjuvant Therapy [Part 1]
- Group 3: Arm 2A: AAPL Adjuvant Therapy [Part 2]
- Group 4: Arm 2B: Observation [Part 2]
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 30 Other Conditions - This treatment demonstrated efficacy for 30 other conditions.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Does the FDA recognize Abiraterone Acetate as a therapeutic option?
"Abiraterone acetate has been assigned a safety rating of 2, as the clinical trials have only provided some evidence to affirm its security, yet no data on efficacy."
Are there any precedent studies which have studied the efficacy of Abiraterone Acetate?
"Abiraterone acetate was initially investigated in 2001 at Providence Cancer Center. Since then, a total of 798 trials have been completed and 433 studies are currently enlisting participants, with many being conducted out of La Jolla California."
Are there still opportunities to join this research trial?
"At this moment, the recruitment process for this clinical trial has been put on pause. Initially posted in October 2016 and last updated in November 2022, no new candidates are being accepted at present. However, there is an abundance of other medical studies devoted to prostate cancer (1315) and Abiraterone acetate specifically (433)."
What therapeutic purpose is Abiraterone Acetate employed for?
"Abiraterone acetate has proven to be effective in combating prostate cancer that is non-metastatic, ulcerative colitis and varicella-zoster virus acute retinal necrosis."
How many people can partake in this medical experiment?
"This research project is no longer accepting new participants. The trial was first made visible on October 19th 2016 and has not been updated since November 2nd 2022. However, there are 1315 trials currently open to prostate cancer patients and 433 clinical studies recruiting for Abiraterone acetate treatment."
Share this study with friends
Copy Link
Messenger